Response to the letter by Boon and colleagues

We appreciate the letter by Boon and colleagues[1], highlighting a number of points important for studies of head and neck cancer in general and proton therapy in particularly. The varied approaches adopted in the current four randomized trials, alongside the non-randomized model-based selection in the Netherlands, underscore the variation of relevant endpoints of toxicity, which is, by definition, multifaceted[2]. We believe that the diversity in approach may actually be a strength, particularly if these studies can be analysed together at a later stage.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Letter to the Editor Source Type: research